Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Adjunct Effects of Bitter Melon Blood-Sugar-Modulating Protein and Metformin on Glycemic and Lipid Control

ABSTRACT: Interactions between botanical supplements and standard antidiabetic therapies remain poorly understood. This study investigated the efficacy and mechanistic properties of a bitter melon blood-sugar-modulating protein (BMP) in relation to concurrent metformin use for improving glucose and lipid metabolism. A translational approach combined mechanistic evaluation in db/db mice with an exploratory, real-world observational cohort study of 119 individuals with prediabetes or diabetes. In db/db mice, BMP significantly reduced fasting blood glucose and HbA1c, with greater glucose-lowering efficacy observed when combined with metformin compared to metformin alone. Skeletal muscle transcriptomic analysis identified coordinated regulation of 27 shared pathways involved in glucose and lipid metabolism. Preclinical data demonstrate coordinated pathway remodeling in skeletal muscle and improved glycemic control when BMP is combined with metformin.

ORGANISM(S): Mus musculus

PROVIDER: GSE341666 | GEO | 2026/09/02

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Multi-tissue transcriptomic landscape reveals synergistic mechanisms of exercise and GLP-1 agonist in ameliorating diabetic phenotypes in db/db mice [Muscle]

Project description:Type 2 diabetes mellitus (T2DM) involves coordinated multi-organ metabolic dysfunction, yet the systems-level effects of combined pharmacological and exercise interventions remain unclear. Male db/db mice received semaglutide, high-intensity interval training (HIIT), or both for eight weeks. Multi-organ bulk RNA-seq with qPCR validation and CellChat analysis was performed in heart, kidney, liver, hippocampus, and skeletal muscle. Combined treatment produced the greatest reductions in food intake, body weight, and fasting glucose. Transcriptomic responses were organ-dependent, most pronounced in skeletal muscle and liver. Under combination therapy, DEGs in hippocampus and liver no longer reached thresholds relative to single interventions, consistent with unchanged hippocampal Glp1r and hepatic Plpp7 by qPCR, whereas heart, kidney, and skeletal muscle retained concordant regulation with further reductions in cardiac Cyp2ab1 and renal/muscle Apoa1. Cross-organ analysis identified coordinated modulation of the PPARα–Plin4 axis and suppression of lipid metabolic pathways, confirmed by qPCR. Inter-organ network analysis revealed increased communication numbers but reduced interaction strength under combination therapy. These findings demonstrate organ-specific transcriptional adaptation to combined HIIT and semaglutide.

2026-08-11 | GSE342847 | GEO

Multi-tissue transcriptomic landscape reveals synergistic mechanisms of exercise and GLP-1 agonist in ameliorating diabetic phenotypes in db/db mice [Brain_RNAseq]

2026-08-18 | GSE343127 | GEO

Multi-tissue transcriptomic landscape reveals synergistic mechanisms of exercise and GLP-1 agonist in ameliorating diabetic phenotypes in db/db mice [Heart_RNAseq]

2026-08-18 | GSE343124 | GEO

Multi-tissue transcriptomic landscape reveals synergistic mechanisms of exercise and GLP-1 agonist in ameliorating diabetic phenotypes in db/db mice

2026-08-08 | GSE341948 | GEO

Effects of imeglimin and metformin on islets of db/db mice

Project description:To investigate the effects of imeglimin and metformin on islet cells in db/db mice, we isolated pancreatic islets from db/db mice treated with/without imeglimin and metformin or db/+ mice.

2023-06-19 | GSE228726 | GEO

Redox state and altered pyruvate metabolism contribute to a dose-dependent metformin-induced lactate production of human myotubes

Project description:Metformin-induced lactate production can lead to lactate acidosis as life-threatening side effect, whereas lactate in a physiological range might also be involved in the therapeutic effect. How metformin increases systemic lactate concentrations is only partly understood. Since human skeletal muscle has a high capacity to produce lactate, we aim to elucidate the potential contribution of skeletal muscle and the dose-dependent regulation of metformin-induced lactate production in primary human myotubes after 48 h of metformin treatment (16-776 μM). At 78 µM, metformin induced lactate production and glucose consumption. Investigating the cellular redox state by mitochondrial respirometry, we found metformin to inhibit the respiratory chain complex I (776 µM, p<0.01) along with a decreased [NAD+]:[NADH] ratio (776 µM, p<0.001). RNA sequencing and phospho-immunoblot data indicate inhibition of pyruvate oxidation mediated through phosphorylation of PDH complex (39 µM, p<0.01). In vivo in human skeletal muscle, we found pyruvate metabolism altered by exercise and not by metformin. Nonetheless, blood lactate levels in the pre-exercise condition are increased under metformin treatment (p<0.05). Metformin-induced inhibition of pyruvate oxidation combined with altered cellular redox state, both shift the equilibrium of the LDH reaction leading to enhanced lactate production of human myotubes.

2023-09-04 | GSE229658 | GEO

Transcription profiling of the effect of metformin (50mg/kg,400mg/kg) on gene expression in livers of db/db mice

Project description:Effect of metformin (50mg/kg,400mg/kg) on gene expression in livers of db/db mice.

2006-11-18 | E-MEXP-490 | biostudies-arrayexpress

mouse gut metagenome

Project description:metformin and db/db mice Metagenome

| PRJNA306645 | ENA

Exploring Protein Relative Relations in Skeletal Muscle Proteomic Analysis for Insights into Insulin Resistance and Type 2 Diabetes

Project description:We performed library-based DIA proteomic analysis of post-exercise skeletal muscle biopsies collected from individuals which spanned a range of glucose metabolism disorders: normal, prediabetes, and T2D. To identify significant protein relations indicative of each specific category, we utilized the Relative Evolutionary Hierarchical Analysis (REHA), which employs interpretable, white-box techniques. anna.czajkowska@umb.edu.pl piotr.zabielski@umb.edu.pl

2024-08-10 | PXD051677 | Pride

Combinatorial targeting of glycolysis and oxidative phosphorylation suppresses tumor growth and metastases.

Project description:The Warburg effect, consisting of increased glucose uptake and glycolysis, provides metabolic energy as well as cellular building blocks for tumor growth. Inhibition of the Warburg effect with 2-deoxyglucose (2DG) has been explored in clinical trials with limited efficacy. Blockage of glycolysis can induce autopahgy resulting in alternative energy generation through oxidative phosphorylation providing a potential bypass of the effects of inhibition of glycolysis. Here in we demonstrate that activation of AMPK, as a consequence of energetic stress, induces mitochondrial energy production potentially bypassing the effects of glycolysis inhibition. We thus combined blockage of glycolysis by 2DG with inhibition of the electron transfer complex I (ETC1) in the mitochondria with the clinically applicable antidiabetic drug metformin. The combination resulted in activation of AMPK and autopahgy that however rendered eventual depletion of ATP and cell death. Furthermore, combined inhibition of glycolysis and mitochondrial respiration inhibited tumor growth and markedly decreased metastatic capacity in vivo. In order to understand the mechanism of these metabolic inhibitors, we performed whole genome transcriptional analysis. Human SK-4 esophageal cancer cell lines were treated with 5 different treatment groups [2 deoxy glucose (4mM), Metformin (5mM), AICAR (2mM), 2 deoxy glucose (4mM) plus Metformin (5mM) and 2 deoxy glucose (4mM) plus AICAR (2mM)] with non treated control groups for 12 hrs. Each groups was quadruplicated. Microarray experiments and data analysis were done at Dept. of Systems Biology, MDACC (Houston, USA)

2012-12-31 | E-GEOD-16816 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data